What is the official website of Astellas Pharma ?

The official website of Astellas Pharma is http://www.astellas.com/.

What is Astellas Pharma's cybersecurity risk score?

Astellas Pharma has an AI-generated cybersecurity risk score of 800 out of 1000, indicating a Good security posture according to Rankiteo's assessment.

How many security incidents has Astellas Pharma experienced?

According to Rankiteo, Astellas Pharma currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Astellas Pharma been affected by any supply chain cyber incidents ?

According to Rankiteo, Astellas Pharma has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Astellas Pharma have SOC 2 Type 1 certification ?

According to Rankiteo, Astellas Pharma is not certified under SOC 2 Type 1.

Does Astellas Pharma have SOC 2 Type 2 certification ?

According to Rankiteo, Astellas Pharma does not hold a SOC 2 Type 2 certification.

Does Astellas Pharma comply with GDPR ?

According to Rankiteo, Astellas Pharma is not listed as GDPR compliant.

Does Astellas Pharma have PCI DSS certification ?

According to Rankiteo, Astellas Pharma does not currently maintain PCI DSS compliance.

Does Astellas Pharma comply with HIPAA ?

According to Rankiteo, Astellas Pharma is not compliant with HIPAA regulations.

Does Astellas Pharma have ISO 27001 certification ?

According to Rankiteo,Astellas Pharma is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Astellas Pharma operate in ?

Astellas Pharma operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Astellas Pharma have ?

Astellas Pharma employs approximately 12,597 people worldwide.

Does Astellas Pharma own any subsidiaries ?

Astellas Pharma presently has no subsidiaries across any sectors.

How many LinkedIn followers does Astellas Pharma have ?

Astellas Pharma's official LinkedIn profile has approximately 745,488 followers.

What is the NAICS classification code for Astellas Pharma ?

Astellas Pharma is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Astellas Pharma have a Crunchbase profile ?

No, Astellas Pharma does not have a profile on Crunchbase.

Does Astellas Pharma have a LinkedIn profile ?

Yes, Astellas Pharma maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/astellaspharmainc.

How many cybersecurity incidents has Astellas Pharma experienced ?

As of September 9, 2026, Rankiteo reports that Astellas Pharma has not experienced any cybersecurity incidents.

How many peer or competitor companies does Astellas Pharma have ?

Astellas Pharma has an estimated 5,760 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Astellas Pharma

Boost Score +25 with badge (5 left)

800

/1000

Good

825

/1000

Good

Astellas Pharma Vendor Cyber Rating & Cyber Score

astellas.com

Add Your Compliance Badge

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Astellas Pharma

Astellas Pharma CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Astellas Pharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Astellas Pharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Astellas Pharma in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Astellas Pharma in 2026.

Incident Types Astellas Pharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Astellas Pharma in 2026.

Incident History - Astellas Pharma (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Astellas Pharma Subsidiaries

Astellas Pharma

Pharmaceutical Manufacturing

Website: http://www.astellas.com/

Company Size: 10,001+ employees

Astellas Gene TherapiesBiotechnology Research

Loading…

Astellas Pharma Similar Companies

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Loading…

NEWS

Astellas Pharma CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 03, 2026 08:00 AM

Five trends shaping modern business services centers in Poland

In 2026 some service centers will close or cut headcount, while smaller and more specialized will emerge. A major AI-driven shift is ahead.

Read Article

September 23, 2024 07:00 AM

The White House, Microsoft, SaS, Foley Hoag & Astellas Offer AI Guidance to Investors. Part One: The Present

Before companies and investors look towards the future, they must first understand the opportunities and challenges AI presents to them.

Read Article

May 04, 2023 06:05 PM

Astellas acquires Iveric bio

Jones Day advised Astellas Pharma Inc. in the $5.9 billion cash acquisition of Iveric bio, Inc., a science-driven biopharmaceutical company focused on the...

Read Article

January 30, 2023 08:00 AM

Microsoft surpasses $20B in security revenue as enterprise customers consolidate

The company's cybersecurity business is growing, but CEO Satya Nadella warned that customers, in an uncertain economy, are exercising...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-86564

SUMMARY

A flaw was found in DPDK lib/vhost. Missing length validation before reading command_data in the virtio-net control-queue handler can cause an out-of-bounds read and a host process crash.

Published

Date2026-09-08

Updated

Date2026-09-08

RISK INFORMATION (Score: 3.3)

cvss3

Base Score: 3.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

1.8

REFERENCES

CVE-2026-55250

SUMMARY

Maravel, a PHP framework oriented towards dependency injection, prior to version 10.74.0 has a high-severity Token Replay Vulnerability arising from a structural lifecycle mismatch between stateless token validation engines and high-performance relational caching layers. Any application with low cache memory that causes premature eviction to free up memory and applications running macropay-solutions/maravel-framework that utilize tymon/jwt-auth for API token authentication and blacklist management or any other package that does the same may be affected. This architectural risk might also impact native Laravel applications utilizing cache tags under specific volatile or eviction-capped environments. tymon/jwt-auth automatically probes for cache tag support. If found, it forcefully wraps 14-day token blacklist entries (jti) inside a relational tymon.jwt tag. In environments where the O(1) Atomic Lazy Eviction model is active — either natively inside Maravel-Framework v20.x or manually backported into v10.x via the explicit DI container singletons provided in PR #104 (App\Cache\TaggedCache and App\Cache\TagSet) — a strict global tracking ceiling (Container::TAGGED_CACHE_TTL_CAP_SECONDS) of 7,200 seconds (2 hours) is enforced to secure the system against memory index bloat. This ceiling forcefully truncates the 14-day blacklist lifespan down to a maximum of 2 hours, after which individual tracking keys naturally expire and disappear from the active cache window. Furthermore, because the optimized engine implements a generational version matrix to achieve O(1) flush speeds, any programmatic or manual invocation of a tag flush or reset (e.g., Cache::tags([...])->flush()) instantly bumps the internal atomic master version pointer. This shifts the computed cryptographic composite hash (sha1($this->tags->getNamespace())) for all overlapping components, rendering the entire existing index immediately unreachable. Consequently, through either natural 2-hour expiration or an intervening tag flush execution (like the cache naturally cleaning old values to free up memory), the invalidation state records are entirely wiped out. Because the tokens' physical cryptographic signatures remain structurally valid for up to 14 days, stolen, hijacked, or legitimately logged-out tokens are instantly and silently resurrected across the entire API gateway, leaving the application critically vulnerable to widespread Token Replay Attacks. Because this issue is caused by an upstream architectural assumption within the tymon/jwt-auth package rather than a core defect inside the framework, there is no direct framework version upgrade that can safely bypass this lifecycle collision without breaking business cache recycling bounds. Maravel version 10.74.0 introduced a way to backport the new fixed tagged cache from 20.x into 10.x by resolving TagSet and TaggedCache from DI, which is how this latent architectural lifecycle vulnerability was discovered. Users must apply the decoupled configuration workaround outlined below. As a workaround, make sure that cache memory size does not generate early natural evictions from cache to free up space, deleting blacklisted jwt ids before they expire. Applications must decouple flat authentication vectors from the relational tagging subsystem. This forces token identifiers to write directly to the primary cache keyspace as flat, un-tagged key-value pairs where they securely retain their unclipped 14-day lifecycle.

Published

Date2026-09-08

Updated

Date2026-09-08

RISK INFORMATION (Score: )

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-53639

SUMMARY

Sylius is an Open Source eCommerce Framework on Symfony. Starting in version 2.0.0 and prior to version 2.0.18, 2.1.15, and 2.2.6, the `GET /api/v2/shop/payment-requests/{hash}` and `PUT /api/v2/shop/payment-requests/{hash}` endpoints look up the payment request solely by the hash from the URL. No ownership check is performed against the authenticated customer or the underlying order. An attacker who obtains a payment request hash can read the payment request and, through the `payment` IRI in the response, recover the underlying order's `tokenValue` (which itself grants access to the full order, items, addresses, customer email, totals); and/or update the payment request payload (e.g. `target_path`, `after_path`). These fields are used by the front-end controller to redirect the user after the payment, so an attacker can flip them to an attacker-controlled URL and intercept the buyer. The hash is a UUID, so it has to be obtained out-of-band (logs, shared links, referrer headers, a co-located client), but once it is known no other credential is required, neither authentication nor knowledge of the order token. The creation endpoint `POST /api/v2/shop/orders/{tokenValue}/payment-requests` shares the same flaw: it resolves the target order solely from the `tokenValue` in the URL without verifying that the caller owns the order. The issue is fixed in versions 2.0.18, 2.1.15, and 2.2.6. As a workaround, add a query extension that filters the `GET` operation; decorate the `PUT` state provider, guard the `POST` creation endpoint with a command-bus middleware, and wire the services.

Published

Date2026-09-08

Updated

Date2026-09-08

RISK INFORMATION (Score: )

cvss4

Base Score: 6.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/Sylius/Sylius/security/advisories/GHSA-mr9r-h354-966r

CVE-2026-53638

SUMMARY

Sylius is an Open Source eCommerce Framework on Symfony. Starting in version 2.0.0 and prior to version 2.0.18, 2.1.15, and 2.2.6, an authorization bypass vulnerability exists in the shop account API. The `PATCH /api/v2/shop/account/orders/{tokenValue}/payments/{paymentId}` endpoint, used by an authenticated shop customer to change the payment method of an order that has been placed but not yet paid (state `STATE_NEW`), does not validate that the chosen payment method is enabled for the order's channel. The equivalent checkout endpoint (`PATCH /api/v2/shop/orders/{tokenValue}/payments/{paymentId}`) correctly rejects out-of-channel payment methods with `HTTP 422`; the account endpoint silently accepts them and returns `HTTP 200`. An authenticated customer can therefore assign any globally enabled payment method to their own placed order, including methods that the store operator has explicitly excluded from that channel. The issue is fixed in versions: 2.0.18, 2.1.15, 2.2.6 and above. As a workaround, decorate the `Sylius\Bundle\ApiBundle\Changer\PaymentMethodChangerInterface` service in the application.

Published

Date2026-09-08

Updated

Date2026-09-08

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://github.com/Sylius/Sylius/security/advisories/GHSA-6955-hrm5-c4qp

CVE-2026-53637

SUMMARY

Sylius is an Open Source eCommerce Framework on Symfony. Versions 2.0.0 through 2.0.17, 2.1.0 through 2.1.14, and 2.2.0 through 2.2.5 contain an improper workflow enforcement vulnerability in the cart `FormComponent`. When an order is completed while its cart page remains open, the stale LiveComponent does not detect the order’s changed state and continues to permit cart actions, allowing an authenticated customer to modify or permanently delete an already completed order. Versions 2.0.18, 2.1.15, and 2.2.6 contain a patch. As a workaround, deployments can copy the patched `FormComponent` into the application's `src/` directory and override the `sylius_shop.twig.component.cart.form` service definition to use that class.

Published

Date2026-09-08

Updated

Date2026-09-08

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://github.com/Sylius/Sylius/security/advisories/GHSA-5597-7rmh-97q5

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Astellas Pharma Vendor Cyber Rating & Cyber Score

Astellas Pharma A.I CyberSecurity Scoring

Astellas Pharma CyberSecurity News & History

Astellas Pharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Astellas Pharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Astellas Pharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Astellas Pharma (X = Date, Y = Severity)

Astellas Pharma Subsidiaries

Astellas Pharma

Astellas Pharma Similar Companies

Alembic Pharmaceuticals Limited

Intas Pharmaceuticals

Johnson & Johnson Innovative Medicine

AbbVie

Servier

Dr. Reddy's Laboratories

Parexel

Merck Group

Bristol Myers Squibb

Astellas Pharma CyberSecurity News

Five trends shaping modern business services centers in Poland

The White House, Microsoft, SaS, Foley Hoag & Astellas Offer AI Guidance to Investors. Part One: The Present

Astellas acquires Iveric bio

Microsoft surpasses $20B in security revenue as enterprise customers consolidate

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Astellas Pharma CyberSecurity News & History

Astellas Pharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Astellas Pharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Astellas Pharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Astellas Pharma (X = Date, Y = Severity)

Astellas Pharma Subsidiaries

Astellas Pharma

Astellas Pharma Similar Companies

Alembic Pharmaceuticals Limited

Intas Pharmaceuticals

Johnson & Johnson Innovative Medicine

AbbVie

Servier

Dr. Reddy's Laboratories

Parexel

Merck Group

Bristol Myers Squibb

Astellas Pharma CyberSecurity News

Five trends shaping modern business services centers in Poland

The White House, Microsoft, SaS, Foley Hoag & Astellas Offer AI Guidance to Investors. Part One: The Present

Astellas acquires Iveric bio

Microsoft surpasses $20B in security revenue as enterprise customers consolidate

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo